Editas Medicine, Inc.
Editas Medicine, Inc. is listed today as Editas Medicine, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2015 | $120 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Editas Medicine, Inc., its revenue in fiscal 2025 came from these business segments: Reportable $40.52 million (100%).
Annual report (SEC XBRL) · Dec 2025
Editas Medicine, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2015).
SEC Form D · Aug 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2015
Products and services#
No products or services of Editas Medicine, Inc. are on record.
Investors#
20 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| bng0, LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Healthcare Innovations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Mgmt HIF, L.P | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship Ventures Fund IV General Partner LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship Ventures Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Flagship Ventures Fund IV-Rx, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Katrine Bosley | Person | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| Polaris Venture Management Co. VI, L.L.C. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Polaris Venture Partners Founders' Fund VI, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Polaris Venture Partners VI, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Third Rock Ventures GP III, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Third Rock Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| TRV GP III, LLC | Other | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Viking Global Investors LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Viking Global Opportunities GP LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Viking Global Opportunities Portfolio GP LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 43 investors.
Largest shareholders today
Institutions holding Editas Medicine, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$37 M9.33%
- TCG Crossover Management, LLC$29 M7.20%
- Ra Capital Management, L.P.$23 M5.76%
- Commodore Capital LP$23 M5.76%
- ADAR1 Capital Management, LLC$23 M5.76%
- Paradigm Biocapital Advisors LP$19 M4.91%
- State Street Corp$18 M4.56%
- Vanguard Capital Management LLC$16 M3.94%
- Vanguard Portfolio Management LLC$12 M3.03%
- Geode Capital Management, LLC$10 M2.52%
- Woodline Partners LP$9 M2.30%
- Vivo Capital, LLC$9 M2.30%
- Opaleye Management Inc.$9 M2.26%
- Goldman Sachs Group Inc$8 M2.10%
- D. E. Shaw & Co., Inc.$8 M2.07%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alexandra Glucksmann | Executive officer | Aug 2015 |
| Andrew Hack | Executive officer | Aug 2015 |
| Katrine Bosley | Executive officer | Aug 2015 |
| Vic Myer | Executive officer | Aug 2015 |
| Alexis Borisy | Director | Aug 2015 |
| Boris Nikolic | Director | Aug 2015 |
| Douglas Cole | Director | Aug 2015 |
| Katrine Bosley | Director | Aug 2015 |
| Kevin Bitterman | Director | Aug 2015 |
About
Discovery-phase pharmaceutical company.
Went public since 2016. Its SEC number is that of a company listed on a stock exchange.